[go: up one dir, main page]

AR130904A1 - Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8 - Google Patents

Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8

Info

Publication number
AR130904A1
AR130904A1 ARP230102893A ARP230102893A AR130904A1 AR 130904 A1 AR130904 A1 AR 130904A1 AR P230102893 A ARP230102893 A AR P230102893A AR P230102893 A ARP230102893 A AR P230102893A AR 130904 A1 AR130904 A1 AR 130904A1
Authority
AR
Argentina
Prior art keywords
antibody
drug conjugate
salt
present
dual agonist
Prior art date
Application number
ARP230102893A
Other languages
English (en)
Inventor
Michinori Akaiwa
Yohei Seki
Yinghua Wang
Ramos Javier Miguelez
Kei Ohnuki
Takashi Kamikubo
Toru Asano
Akio Kamikawa
Takashi Chaen
Rika Hoshi
Shinji Soga
Chulwon Kwon
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of AR130904A1 publication Critical patent/AR130904A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

El objeto de la presente invención proporciona una composición farmacéutica para prevenir o tratar diversos cánceres mediante el desarrollo de un conjugado de anticuerpo-fármaco o una sal del mismo que contiene un compuesto agonista dual TLR7/8. Los presentes inventores encontraron un compuesto o una sal del mismo que tiene una acción agonista dual TLR7/8, estudiaron un conjugado de anticuerpo-fármaco que puede utilizarse como un ingrediente activo de una composición farmacéutica para prevenir o tratar diversos cánceres y encontraron / aclararon que el conjugado de anticuerpo-fármaco o una sal del mismo según la presente invención tiene un efecto sobre la producción de TNF-a e INF-g y un efecto antitumoral in vivo y puede utilizarse para la prevención o el tratamiento del cáncer. También encontraron un anticuerpo anti-CLDN6 para su uso en un conjugado de anticuerpo-fármaco o una sal del mismo según la presente invención. El conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual TLR7/8 o una sal del mismo según la presente invención y el compuesto de la fórmula (2) o una sal del mismo según la presente invención tiene un efecto sobre la producción de TNF-a e INF-g y un efecto antitumoral in vivo y se espera que se utilice en un agente profiláctico o terapéutico para el cáncer.
ARP230102893A 2022-10-31 2023-10-30 Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8 AR130904A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2022174538 2022-10-31

Publications (1)

Publication Number Publication Date
AR130904A1 true AR130904A1 (es) 2025-01-29

Family

ID=90930522

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP230102893A AR130904A1 (es) 2022-10-31 2023-10-30 Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8

Country Status (10)

Country Link
US (2) US12390536B2 (es)
EP (1) EP4566633A1 (es)
JP (1) JPWO2024095964A1 (es)
KR (1) KR20250097820A (es)
CN (1) CN119947760A (es)
AR (1) AR130904A1 (es)
AU (1) AU2023373601A1 (es)
MX (1) MX2025004265A (es)
TW (1) TW202434302A (es)
WO (1) WO2024095964A1 (es)

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2241578B1 (en) 2008-01-11 2016-04-20 The University of Tokyo Anti-cldn6 antibody
RU2675997C2 (ru) 2009-11-11 2018-12-25 Ганимед Фармасьютикалз Аг Антитела, специфичные к клаудину 6 (cldn6)
EP3421496B1 (en) 2011-05-13 2024-08-07 Astellas Pharma Inc. Antibodies for treatment of cancer expressing claudin 6
IN2014CN04615A (es) 2011-12-22 2015-09-18 Astellas Pharma Inc
CN112587658A (zh) 2012-07-18 2021-04-02 博笛生物科技有限公司 癌症的靶向免疫治疗
NZ724878A (en) * 2014-05-01 2019-03-29 Novartis Ag Compounds and compositions as toll-like receptor 7 agonists
MA44334A (fr) * 2015-10-29 2018-09-05 Novartis Ag Conjugués d'anticorps comprenant un agoniste du récepteur de type toll
AR111651A1 (es) 2017-04-28 2019-08-07 Novartis Ag Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
US10487084B2 (en) * 2017-08-16 2019-11-26 Bristol-Myers Squibb Company Toll-like receptor 7 (TLR7) agonists having a heterobiaryl moiety, conjugates thereof, and methods and uses therefor
JP2022500414A (ja) 2018-09-12 2022-01-04 シルバーバック セラピューティックス インコーポレイテッド 免疫刺激性コンジュゲートにより疾患を処置する方法および組成物
JP7706210B2 (ja) * 2019-06-10 2025-07-11 ストロ バイオファーマ インコーポレーテッド ５Ｈ－ピロロ［３，２－ｄ］ピリミジン－２，４－ジアミノ化合物およびその抗体コンジュゲート
EP3980080A1 (en) 2019-06-10 2022-04-13 Sutro Biopharma, Inc. Immunomodulator antibody drug conjugates and uses thereof
TW202126658A (zh) * 2019-09-29 2021-07-16 大陸商江蘇恆瑞醫藥股份有限公司 吡咯并雜芳基衍生物或其偶聯物、其製備方法及其應用
WO2021067644A1 (en) * 2019-10-01 2021-04-08 Silverback Therapeutics, Inc. Combination therapy with immune stimulatory conjugates
TW202227478A (zh) 2020-09-15 2022-07-16 德商拜恩迪克公司 對細胞靶向遞送的藥劑及方法
JP6976016B1 (ja) 2021-05-11 2021-12-01 ガルファ株式会社 化石資源増量装置

Also Published As

Publication number Publication date
JPWO2024095964A1 (es) 2024-05-10
US12390536B2 (en) 2025-08-19
US20250025567A1 (en) 2025-01-23
TW202434302A (zh) 2024-09-01
AU2023373601A1 (en) 2025-04-03
US20250312471A1 (en) 2025-10-09
WO2024095964A1 (ja) 2024-05-10
CN119947760A (zh) 2025-05-06
KR20250097820A (ko) 2025-06-30
EP4566633A1 (en) 2025-06-11
MX2025004265A (es) 2025-05-02

Similar Documents

Publication Publication Date Title
CL2023000848A1 (es) Terapia de combinación que incluye inhibidor de krasg12c y agente farmacéuticamente activo para tratar cáncer
MX2024004846A (es) Compuesto tetraciclico que contiene nitrogeno, metodo de preparacion del mismo y uso medico del mismo.
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
AR058620A1 (es) Formulacion farmaceutica para el suministro de compuestos inhibidores del receptor de tirosina quinasa (rtki) al ojo
CO6300964A2 (es) Una composicion farmaceutica que comprende una combinacion de un agente quimioterapeutico y un anticuerpo 3 antiglipicano
CO2024006160A2 (es) Conjugado de anticuerpo bispecífico-fármaco de camptotecina y uso farmacéutico de este
MX2021005240A (es) Combinacion de inhibidores de peque?as moleculas cd-47 con otros agentes anticancer.
MX2023004299A (es) Direccionamiento de células t cd4+ in vivo para terapeuticos de arnm.
AR096526A1 (es) Agentes citotóxicos para el tratamiento del cáncer
BR112018076639A2 (pt) quimioterapias de combinação
BR112023000220A2 (pt) Formulações de longa ação
CL2022002150A1 (es) Moléculas de unión a antígeno anti-cd137 para su administración en el tratamiento contra el cáncer
BR112022019864A2 (pt) Composto de oxofenilarsina deuterada e uso do mesmo
CO2025008047A2 (es) Conjugados de anticuerpo ceacam5-fármaco y métodos de uso de los mismos
MX391965B (es) Compuestos de porfirina y composiciones útiles para el tratamiento de cáncer.
AR130904A1 (es) Conjugado de anticuerpo-fármaco que contiene un compuesto agonista dual del receptor tipo toll 7/8
CR20250060A (es) Anticuerpos anti monometil auristatina y fragmentos de anticuerpos.
CO2023009635A2 (es) Conjugado de anticuerpo anti-dll3-fármaco
EA201991069A1 (ru) Комбинированная терапия ингибитором фосфоинозитид-3-киназы и связывающим цинк агентом
MX2022002555A (es) Conjugados de farmaco de anticuerpo de union a receptor de tipo ii de la hormona anti-mulleriana humana (amhrii) y uso de los mismos en el tratamiento de canceres.
BR112023023398A2 (pt) Usos de um conjugado anticorpo-droga em combinação com um inibidor de checkpoint imune e de uma quantidade eficaz de conjugado anticorpo-droga e um inibidor de checkpoint imune, método para tratar um paciente com câncer urotelial, e, composição farmacêutica
CO2025008528A2 (es) Anticuerpo anti-cmet, conjugado anticuerpo-fármaco y método de preparación de estos y uso de estos
CO2023017275A2 (es) Composición farmacéutica para tratar o prevenir un trastorno relacionado con la administración de un agente anticancerígeno
PL436660A1 (pl) Kompozycja farmaceutyczna stosowana w leczeniu nowotworów
BR112023026735A2 (pt) Conjugado, composto de conector-fármaco, uso de um composto de conector-fármaco, e, composição farmacêutica

Legal Events

Date Code Title Description
FB Suspension of granting procedure